Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Linomide

National Institutes of Health

Related topics

Related topics

2 relations
LS 2616

Broader (1)

roquinimex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2000
Highly Cited
2000
Linomide in relapsing and secondary progressive MS
Objective: To determine whether linomide (roquinimex) is better than placebo in slowing the time to confirmed clinical worsening… 
  • table 1
  • table 2
  • table 3
Highly Cited
2000
Highly Cited
2000
Linomide in relapsing and secondary progressive MS
Objective: To determine the safety and efficacy of roquinimex (linomide) in the management of relapsing-remitting and secondary… 
  • figure 1
  • figure 2
Highly Cited
1997
Highly Cited
1997
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
In previous studies, we have demonstrated that androgen ablation-induced growth inhibition of androgen-responsive PC-82 and A-2… 
  • table I
  • table 3
  • table 4
Review
1997
Review
1997
Target to apoptosis: A hopeful weapon for prostate cancer
Prostate cancer is the most commonly diagnosed neoplasm and the second leading cause of male death in this country. Multiple… 
Highly Cited
1997
Highly Cited
1997
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Linomide is a p.o. active antiangiogenic agent that has been demonstrated to be effective in suppressing the in vivo growth of… 
  • table 1
  • table 2
  • table 3
  • figure 1
Highly Cited
1996
Highly Cited
1996
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide
Linomide (quinoline-3-carboxamide) is a synthetic immunomodulator that increases the natural killer cell activity. We previously… 
  • figure 1
  • figure 2
Highly Cited
1995
Highly Cited
1995
Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo
In a number of experimental systems in which lymphocyte depletion was induced by apoptosis-inducing manipulations, no apoptotic… 
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
1993
Highly Cited
1993
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Linomide is a synthetic immunomodulator that enhances natural killer cell activity and significantly activates several… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Highly Cited
1993
Highly Cited
1993
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide
Linomide (LS‐2616, quinoline‐3‐carboxamide) is a synthetic immunomodulator that stimulates natural killer cell activity and… 
Highly Cited
1993
Highly Cited
1993
Antiangiogenic effects of the quinoline-3-carboxamide linomide.
Linomide (N-phenylmethyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxoquinoline-3-carboxa mide) has a reproducible in vivo antitumor… 
  • figure I
  • table 2
  • table I
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE